Evidence map›Paper›PMID 37919754›Full record

ArticleCancer cell international2023

NUAK1 promotes tumor metastasis through upregulating slug transcription in esophageal squamous cell carcinoma.

Huiru Yang, Zhen Wei, Yifan Song, Kexin Du, Nannan Yin, Hong Lu, Bingbing Li, Lili Hou, Panfei Xing, Liang Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. NUAK: never underestimate a kinase.Essays in biochemistry · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Huiru YangSchool of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Zhen WeiSchool of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Yifan SongThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Kexin DuThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Nannan YinThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Hong LuDepartment of Oncology, Huaihe Hospital of Henan University, Kaifeng, 475004, Henan, China.
Bingbing LiDepartment of Oncology, Huaihe Hospital of Henan University, Kaifeng, 475004, Henan, China.
Lili HouSchool of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Panfei XingThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China.
Liang ChenThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China. liang88chen@henu.edu.cn.
Chaojie WangThe Key Laboratory of Natural Medicine and Immuno-Engineering, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China. wcjsxq@henu.edu.cn.
Songqiang XieSchool of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, 475004, Henan, China. xiesq@vip.henu.edu.cn.
Henan University · CNHenan University Huaihe Hospital and Huaihe Clinical Institute · CN

Funding

Key Project of Science and Technology Research Funded by the Educational Commission of Henan Province 23A310021National Natural Science Foundation of China 22104029National Natural Science Foundation of China 82103514Project Funded by China Postdoctoral Science Foundation 2022M711050
6 · The paper itself

Abstract

backgroundMetastasis is still a major cause of poor pathological outcome and prognosis in esophageal squamous cell carcinoma (ESCC) patients. NUAK1 has been reported highly expressed in many human cancers and is associated with the poor prognosis of cancer patients. However, the role of NUAK1 and its underlying signaling mechanism in ESCC metastasis remain unclear.

methodsExpression of NUAK1 in ESCC was detected by real-time quantitative RT-PCR (qRT-PCR), Western blotting and immunohistochemical staining. MTT, colony formation, wound-healing and transwell assays were used to determine the role NUAK1 in vitro. Metastasis was evaluated by use of an experimental pulmonary metastasis model in BALB/c-nu/nu mice. The mechanisms were assessed by using coimmunoprecipitation, immunofluorescence and dual-luciferase reporter gene experiments.

resultsNUAK1 was highly expressed in ESCC tissues compared with the adjacent normal esophageal epithelial tissues. Moreover, the elevated expression of NUAK1 positively correlated with tumor invasion depth, lymph node metastasis, pathological TNM stage, and poor survival in ESCC patients. Further experiments showed that NUAK1 overexpression did not change the cell viability and colony formation of ESCC cells, while remarkably promoted the migration and invasion in vitro and experimental pulmonary metastasis in vivo. Mechanistically, NUAK1 enhanced the transcription level of Slug, which enhanced the migratory and invasive capability of ESCC cells. Consistently, silencing Slug almost completely diminished the migration and invasion of NUAK1-overexpressing ESCC cells. Further studies demonstrated that NUAK1 upregulated the transcription activity of Slug through activating the JNK/c-Jun pathway.

conclusionThese results demonstrated that NUAK1 promoted the metastasis of ESCC cells through activating JNK/c-Jun/Slug signaling, indicating NUAK1 is a promising therapeutic target for metastatic ESCC.

Indexed as

EMTESCCMetastasisNUAK1Slug

Identifiers

PMID37919754
PMCPMC10621130
OpenAlexW4388275568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.